NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 7 June 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Mariana Bacelar Present for all items
4. Professor Iolo Doull Present for all items
5. Dr Francis Drobniewski Present for all items
6. Dr Daniel Gallacher (Observer) Present for all items
7. Dr Warren Linley Present for all items
8. Dr Andrew Makin (Observer) Present for all items
9. Professor David McAllister Present for all items
10. Dr Alistair Patton Present for all items
11. Anna Pracz Present for all items
12. Gabriel Rogers  Present for all items
13. Dr Toby Smith Present for all items
14. Mary Weatherstone Items 1.1 to 4.1.3
15. Nigel Westwood Present for all items
16. Peter Wheatley-Price Items 1.1 to 4.3.2
17. Dr Stuart Williams Present for all items
18. Tony Wootton Present for all items
19. Carole Pitkeathley Present for all items
20. Malcolm Oswald Present for all items
21. Stephen O’Brien Items 1.1 to 4.3.2

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Richard Diaz, Associate Director Present for all items

Leena Issa, Project Manager Items 1.1 to 4.3.2

Jeremy Powell, Project Manager Items 5.1 to 5.3.2

Lizzie Walker, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Rufaro Kausi, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Anna Willis, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Ross Wilkinson, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

External assessment group representatives present

Neil Scott, Aberdeen HTA Group Items 1.1 to 4.2.1

Graham Scotland, Aberdeen HTA Group Items 1.1 to 4.2.1

Mekazin Tsehaye, Aberdeen HTA Group Items 1.1 to 4.2.1

Nicky Welton, Bristol Technology Assessment Group Items 5.1 to 5.1.4

Deborah Caldwell, Bristol Technology Assessment Group Items 5.1 to 5.1.4

Clinical, Patient & NHS England experts present

Dr John Ingram, Clinical Reader & Consultant Dermatologist, clinical expert nominated by Novartis Items 1.1 to 4.1.3

Dr Ruth Lamb, Consultant Dermatologist, Clinical Expert nominated by British Association of Dermatologists Items 1.1 to 4.1.3

Dr Neil Rabin, Consultant Haematologist , clinical expert nominated by UK Myeloma Forum Items 1.1 to 5.1.4

Ms Shelagh McKinlay, Director of Research and Advocacy, patient expert nominated by Myeloma UK Items 5.1 to 5.1.4

Ms Rosie Dill, patient expert nominated by Myeloma UK Items 5.1 to 5.1.4

Steve Williamson, NHSE CDF, Consultant Pharmacist in Cancer Services, Items 5.1 to xx

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Vice-Chair, Baljit Singh welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Rhiannon Owen, Dr Bushra Hasnie, Dr Hatim Abdulhussien and Dr Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 5 April 2023.
1. **Appraisal of Secukinumab for treating moderate to severe hidradenitis suppurativa ID4039**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11095).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Dr Francis Drobniewski (clinical), and Warren Linley (cost).
	2. Part 2a – Closed session (company representatives, clinical experts, and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11095>
1. **Appraisal of Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]**
	1. Part 1 – Open session
		1. The Chair, Charles Crawley welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Janssen
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10914).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
		4. The committee discussed confidential information submitted for this item.
	2. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10914>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 6 July and will start promptly at 09:30am.